Using a Sequence of Estrogen Response Elements as a DNA Aptamer for Estrogen Receptors in Vitro

Nucleic Acid Therapeutics

Volumn 25, Issue 3, 2015, Pages 152-161

  He, Xu ^a   Chen, Jie ^a   Yie, Shang Mian ^a,b   Ye, Shang Rong ^b   Dong, Dan Dan ^a   Li, Ke ^a  

^a SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b Research and Development Center Sichuan HeLi Bio pharmaceutical Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; OLIGONUCLEOTIDE; PARAFFIN; RECEPTOR ANTIBODY; SINGLE STRANDED DNA; TAMOXIFEN; ESTROGEN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CANCER; BREAST CANCER CELL LINE; BREAST CARCINOMA; CANCER CELL; CANCER DIAGNOSIS; CANCER THERAPY; CELL PROLIFERATION; CELL VIABILITY; CROSS REACTION; CYTOTOXICITY; DNA SEQUENCE; DRUG CYTOTOXICITY; ESTROGEN RESPONSIVE ELEMENT; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SINGLE-STRANDED DNA VIRUS; TISSUE SECTION; VITELLOGENIN A2 GENE; XENOPUS; BREAST TUMOR; FEMALE; GENETICS; MCF 7 CELL LINE; PATHOLOGY; PHYSIOLOGY;

APTAMERS, NUCLEOTIDE; BREAST NEOPLASMS; ESTROGENS; FEMALE; HUMANS; IN VITRO TECHNIQUES; MCF-7 CELLS; RECEPTORS, ESTROGEN;

EID: 84929873101     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2014.0521     Document Type: Article

References (51)

1. Clarke RB. (2003). Steroid receptors and proliferation in the human breast. Steroids 68:789-794.
2. Keen JC and NE Davidson. (2003). The biology of breast carcinoma. Cancer 97:825-833.
3. Allred DC. (2010). Issues and updates: evaluating estrogen receptor-α, progesterone receptor, and HER2 in breast cancer. Mod Pathol 23:S52-S59.
4. rd edition. Harris JR, Lippman ME, Morrow M and Osborne CK, eds. (2004). Lippincott Williams & Wilkins, Philadelphia, pp. 602-617.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717.
6. Howell A, J Cuzick, M Baum, A Buzdar, M Dowsett, JF Forbes, G Hoctin-Boes, J Houghton, GY Locker, JS Tobias and ATAC Trialists' Group. (2005). Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62.
7. Dowsett M, J Cuzick, C Wale, T Howell, J Houghton and M Baum. (2005). Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: a hypothesis-generating study. J Clin Oncol 23:7512-7517.
8. Buzdar A, I Vergote and R Sainsbury. (2004). The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women. Breast J 10:211-217.
9. Al-Mubarak M, AG Sacher, A Ocana, F Vera-Badillo, B Seruga and E Amir. (2013). Fulvestrant for advanced breast cancer: a meta-analysis. Cancer Treat Rev 39:53-758.
10. Croxtall JD and K McKeage. (2011). Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women. Drugs 71:363-380.
11. Rimmele M. (2003). Nucleic Acid aptamers as tools and drugs: recent developments. Chem Biochem 4:963-971.
12. Ma DL and CH Leung. (2013). Editorial for "Recent advances in DNA-based biosensor". Methods 64:183-184.
13. Lin Y, D Nieuwlandt, A Magallanez, B Feistner and SD Jayasena. (1996). High-affinity and specific recognition of human thyroid stimulating hormone (hTSH) by in vitro-selected 2′-amino-modified RNA. Nucleic Acids Res 24:3407-3414.
14. Drolet DW, L Moon-McDermott and TS Romig. (1996). An enzyme-linked oligonucleotide assay. Nat Biotechnol 14:1021-1025.
15. Ulrich H and C Wrenger. (2009). Disease-specific biomarker discovery by aptamers. Cytometry A 75:727-733.
16. Leung KH, HZ He, VP Ma, HJ Zhong, DS Chan, J Zhou, JL Mergny, CH Leung and DL Ma. (2013). Detection of base excision repair enzyme activity using a luminescent G-quadruplex selective switch-on probe. Chem Commun (Camb) 49:5630-563.
17. He HZ, KH Leung, W Wang, DS Chan, CH Leung and DL Ma. (2014). Label-free luminescence switch-on detection of T4 polynucleotide kinase activity using a G-quadruplex-selective probe. Chem Commun (Camb) 50:5313-5315.
18. Ma DL, S Lin, KH Leung, HJ Zhong, LJ Liu, DS Chan, A Bourdoncle, JL Mergny, HM Wang and CH Leung. (2014). An oligonucleotide-based label-free luminescent switch-on probe for RNA detection utilizing a G-quadruplex-selective iridium (III) complex. Nanoscale 6:8489-8494.
19. Davis KA, B Abrams, Y Lin and SD Jayasena. (1996). Use of a high affinity DNA ligand in flow cytometry. Nucleic Acids Res 24:702-706.
20. Davis KA, Y Lin, B Abrams and SD Jayasena. (1998). Staining of cell surface human CD4 with 2′-F-pyrimidine containing RNA aptamers for flow cytometry. Nucleic Acids Res 26:3915-3924.
21. Sánchez MI, C Penas, ME Vázquez and JL Mascareñas. (2014). Metal-catalyzed uncaging of DNA-binding agents in living cells. Chem Sci 5:1901-1907.
22. Barbas AS and RR White. (2009). The development and testing of aptamers for cancer. Curr Opin Investig Drugs 10:572-578.
23. Ray P and RR White. (2010). Aptamers for targeted drug delivery. Pharmaceuticals 3:1761-1778.
24. Bunka DHJ and PG Stockley. (2006). Aptamers come of age-at last. Nat Rev Microbiol 4:588-596.
25. Sun S. (2000). Technology evaluation: SELEX, Gilead Sciences Inc. Curr Opin Mol Ther 2:100-105.
26. Gruber CJ, DM Gruber, IML Gruber, F Wieser and JC Huber. (2004). Anatomy of the estrogen response element. TRENDS in Endoc Metab 15:73-78.
27. Klein-Hitpa L, M Schorpp, U Wagner and GU Ryffel. (1986). An estrogen-responsive element derived from the 5′flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells. Cell 46:1053-1061.
28. Klinge CM. (2001). Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 29:2905-2919.
29. Jhaveri SD, Ellington AD. (2001). In vitro selection of RNA aptamers to a protein target by filter immobilization. Curr Protoc Nucleic Acid Chem Chapter 9, Unit 9.3.
30. Stoica A, M Saceda, A Fakhro, HB Olomon, BD Fenster and MB Martin. (1997). The role of transforming growth factor-b in the regulation of estrogen receptor expression in the MCF-7 breast cancer cell line. Endocrinol 138:1498-1505.
31. Scatchard G. (1949). The attractions of protein for small molecules and ions. Ann NY Acad Sci 51:660-672.
32. Martowicz A, J Rainer, J Lelong, G Spizzo, G Gastl and G Untergasser. (2013). EpCAM overexpression prolongs proliferative capacity of primary human breast epithelial cells and supports hyperplastic growth. Mol Cancer 12:56.
33. Wooge CH, GM Nilsson, A Heierson, DP McDonnell and BS Katzenellenbogen. (1992). Structural requirements for high affinity ligand binding by estrogen receptors: a comparative analysis of truncated and full length estrogen receptors expressed in bacteria, yeast, and mammalian cells. Mol Endocrinol 6:861-869.
34. Ellington AD and JW Szostak. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346:818-822.
35. Tuerk C and L Gold. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505-510.
36. Jayasena SD. (1999). Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 45:1628-1650.
37. Romig TS, C Bell and DW Drolet. (1999). Aptamer affinity chromatography: combinatorial chemistry applied to protein purification. J Chromatogr B Biomed Sci Appl 731:275-284.
38. Burgstaller P, A Girod and M Blind. (2002). Aptamers as tools for target prioritization and lead identification. Drug Discov Today 7:1221-1228.
39. Green LS, C Bell and N Janjic. (2001). Aptamers as reagents for high-throughput screening. Biotechniques 30:1094-1096.
40. Brody EN, MC Willis, JD Smith, S Jayasena, D Zichi and L Gold. (1999). The use of aptamers in large arrays for molecular diagnostics. Mol Diagn 4:381-388.
41. Schafer R, J Wiskirchen, K Guo, B Neumann, R Kehlbach, J Pintaske, V Voth, T Walker, AM Scheule, et al. (2007). Aptamer-based isolation and subsequent imaging of mesenchymal stem cells in ischemic myocard by magnetic resonance imaging. Rofo 179:1009-1015.
42. Nimjee SM, CP Rusconi and BA Sullenger. (2005). Aptamers: an emerging class of therapeutics. Annu Rev Med 5:555-583.
43. Zeng Z, P Zhang, N Zhao, AM Sheehan, CH Tung, CC Chang and Y Zu. (2010). Using oligonucleotide aptamer probes for immunostaining of formalin-fixed and paraffin-embedded tissues. Mod Pathol 23:1553-1558.
44. Sledge GW Jr. (2001). Breast cancer in the clinic: treatments past, treatments future. J Mammary Gland Biol Neoplasia 6:487-495.
45. Osborne CK, A Wakeling and RI Nicholson. (2004). Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 90:S2-S6.
46. Bulzomi P, A Bolli, P Galluzzo, S Leone, F Acconcia and M Marino. (2010). Naringenin and 17β-estradiol coadministration prevents hormone-induced human cancer cell growth. IUBMD Life 62:51-60.
47. Sreeja S, TR Santhosh Kumar, BS Lakshmi and S Sreeja. (2012). Pomegranate extract demonstrate a selective estrogen receptor modulator profile in human tumor cell lines and in vivo models of estrogen deprivation. J Nutr Biochem 23:725-732.
48. Jordan VC. (1993). Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 110:507-517.
49. Davies C, H Pan, J Godwin, R Gray, R Arriagada, V Raina, M Abraham, VH Medeiros Alencar, A Badran, et al.; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. (2013). Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805-816.
50. Bergman L, ML Beelen, MP Gallee, H Hollema, J Benraadt and FE van Leeuwen. (2000). Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 356:881-887.
51. Lønning PE and HP Eikesdal. (2013). Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. Endocr Relat Cancer 20:R183-201.